J&J’s Anti-Tau Asset Posdinemab Fails In Phase II Alzheimer’s Study

AC Immune-Partnered Tau Immunotherapy In Ongoing Trial

 
• By Mandy Jackson
  
Multiple agents are in development targeting tau tangles in Alzheimer's patients' brains (Shutterstock)

More from Scrip

More from Clinical Trials